Skip to content

BRIGHT MINDS BIOSCIENCES INC.

DRUG

CIK 0001827401

← back to feed
Revenue (TTM)
—
FY Sep 2024
Net Income (TTM)
−2.8M
+62.0% YoY FY Sep 2024
EPS Diluted (TTM)
−0.65
+67.2% YoY FY Sep 2024
Gross Margin
—
FY Sep 2024
Operating Margin
—
FY Sep 2024
Net Margin
—
FY Sep 2024
Free Cash Flow (TTM)
—
FY Sep 2024
Cash
5.72M
FY Sep 2024
Total Debt
—
FY Sep 2024
Shares Outstanding
4.52M sh
FY Sep 2024

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings